Tracking systemic therapy resistance of lung and colorectal cancer through targeted NGS analysis of genetic and epigenetic variants in liquid biopsies.

The TRACEPIGEN project addresses a major clinical issue in cancer treatment – the emergence of resistance to systemic drug therapy.

The TRACEPIGEN project focuses on the analysis of circulating cell-free DNA (cfDNA) to study the evolution of genetic and epigenetic landscape in response to systemic therapy to identify biomarkers for dynamic monitoring during cancer progression.

TRACEPIGEN brings together a group of enthusiastic young researchers with complementary skills to work on an ambitious project incorporating cutting-edge methodology with an exciting clinically relevant research question.

Research support

This research was supported by the Science Fund of the Republic of Serbia, PROMIS, #6060876, TRACEPIGEN

Scroll to Top